Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients.

Saved in:
Bibliographic Details
Title: Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients.
Authors: Xie H; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China., Xiang M; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China., Zhang M; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China., Meng F; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China., Qi Y; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China., Chen K; Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China., Zeng D; Department of Hematology, Daping Hospital, Army Medical University, Chongqing, China.
Source: Frontiers in immunology [Front Immunol] 2026 Jun 23; Vol. 17, pp. 1722204. Date of Electronic Publication: 2026 Jun 23 (Print Publication: 2026).
Publication Type: Clinical Trial; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2026.1722204